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Epidemiological evidence suggests a beneficial effect of soy consumption in relation to 
cardiovascular disease and in 1999, the U.S. Food and Drug Administration approved a 
health claim for the cholesterol-lowering effects of soy protein.  However, this effect has 
not always been reproduced in subsequent soy dietary interventions, the results of which 
vary greatly.  Soy beans are the richest dietary source of the isoflavones daidzein, 
genistein and glycitein, which have also been implicated with a role in lipid-lowering due 
to their antioxidant and estrogen receptor activities.  After soy intake, there is large 
variability between individuals in isoflavone bioavailability.  The isoflavones are present 
in soy as glycoside conjugates and after endogenous hydrolysis, the aglycones are 
absorbed, metabolised by liver and intestinal enzymes, distributed to tissues and excreted 
in urine.  Endogenous isoflavone metabolites have been identified; of particular interest 
is the metabolism of daidzein to equol, as this has greater antioxidant and estrogen 
receptor activities than daidzein.  Gut microflora is essential for isoflavone 
bioavailability and metabolism and can be affected by dietary modification.  Differences 
in gut microflora composition may contribute to the large inter-individual variability in 
these processes, which in turn may contribute to variation in the lipid effects of soy 
consumption.  Recently there has been much interest in the identification of dietary 
components that may enhance soy isoflavone bioavailability and it was the aim of this 
thesis to examine the effects of soy foods and other dietary components on soy 
isoflavone bioavailability and lipids.  Four human studies were conducted and isoflavone 
bioavailability was determined based on plasma and urinary isoflavone levels.  These 
samples were extracted with Helix Pomatia juice containing β-glucuronidases and 
sulphatases and the isoflavone aglycones were quantified by HPLC with electrochemical 
detection. 
 
Resistant starch is a prebiotic and therefore has specific effects on gut microflora activity 
in the gastrointestinal tract and it was hypothesised that resistant starch intake may also 
affect isoflavone bioavailability.  A pilot study with nine females (7 Australian and 2 
Kenyan) was conducted to determine the acute and chronic effects of resistant starch 
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intake on soy isoflavone bioavailability.  When resistant starch was consumed in the 
same meal as soy, plasma levels of daidzein and genistein were significantly reduced.  
However, daily resistant starch intake for 2 and 4 weeks prior to a soy meal resulted in a 
trend of increased mean daidzein excretion and of increased equol production in the two 
Kenyan subjects.  It was concluded that resistant starch may enhance equol production, 
possibly dependent on gut microflora, genetics or habitual diet. 
 
To determine whether there was an association between isoflavone bioavailability and 
lipid changes after soy intake, a soy dietary intervention was conducted in 23 
hyperlipidemic men and postmenopausal women.  Plasma and urinary daidzein and 
genistein levels were increased significantly after 6 weeks of soy milk and yoghurt 
intake.  This treatment did not significantly affect lipids and there were no correlations 
between plasma or urinary isoflavone levels and lipid changes.  However, in 8 subjects 
who produced equol in their plasma or urine, soy intake resulted in significant reductions 
in total and LDL cholesterol.  This suggests that metabolism of daidzein to equol may be 
a determinant of the lipid-lowering effects of soy, contributing to this variation. 
 
Based on the findings of the first two studies, a dietary combination of soy (cereal and 
milk) with either a probiotic or a prebiotic was proposed for further examination of the 
effects of resistant starch and equol production on isoflavone bioavailability and lipid 
levels.  In a study of crossover design with 5-week dietary periods, soy consumption was 
compared with intake of soy plus either probiotic yoghurt or resistant starch-enriched 
bread for the effects on plasma and urinary isoflavone levels after a test soy meal in 31 
hyperlipidemic men and postmenopausal women.  Soy intake significantly increased 
circulating plasma daidzein and genistein levels, but did not affect plasma or urinary 
isoflavones after the test soy meal.  There were no additional significant effects of either 
probiotic or prebiotic treatments; however, there was a trend for increased circulating 
plasma daidzein and genistein with probiotic treatment and for increased plasma daidzein 
and genistein 24 hours after the test soy meal with prebiotic treatment.  Probiotic or 
prebiotic treatment did not induce or increase equol production, though there was a trend 
for increased plasma equol in “equol-positive” subjects (n = 12) after probiotic treatment.  
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The lack of any overall significant effects on isoflavone bioavailability with either 
probiotic or prebiotic treatment suggests that even if gut microflora was modified, this 
was not favourable for isoflavone bioavailability or equol production and thus it appears 
that other inherent features may determine these processes.  Total cholesterol was 
significantly decreased with soy plus probiotic or prebiotic intake (-4.7 ± 2.0% and -5.5 ± 
1.6% respectively) and LDL cholesterol was significantly decreased with soy intake and 
with prebiotic treatment (-4.1 ± 2.1% and -7.3 ± 2.2% respectively).  This suggests that 
even in the absence of effects on isoflavone bioavailability, there was synergistic action 
between soy and probiotic or prebiotic intake for lipid-lowering effects and thus 
combination of these dietary components may be useful in lipid management. 
 
For further examination of potential lipid-lowering effects of soy in synergy with other 
dietary components, it was hypothesised that a novel combination of soy with DHA-rich 
oil may also affect isoflavone bioavailability and result in a more positive lipid profile 
than supplementation with either component alone.  DHA supplementation has strong 
triglyceride lowering effects, but it often also results in elevated LDL cholesterol, 
whereas conversely, a reduction in LDL is the most commonly reported lipid effect of 
dietary soy intake.  In a crossover study with 35 hyperlipidemic men and postmenopausal 
women, plasma and urinary isoflavones were significantly increased after 6 weeks of soy 
(cereal) intake, but there were no significant effects of DHA-rich oil supplementation.  
Soy intake did not result in any significant lipid effects; however DHA supplementation 
resulted in a significant increase in HDL and decrease in triglycerides, independent of 
concurrent soy intake.  In addition, there was an influence of the combination of DHA 
and soy compared with DHA alone for total and LDL cholesterol.  While total and LDL 
cholesterol were increased with DHA supplementation alone, significantly for LDL, 
these increases were somewhat attenuated with concurrent soy intake.  This suggests the 
potential for a combination of soy and n-3 fatty acids in producing lipid effects protective 
in relation to cardiovascular disease. 
 
When the latter three studies were compared, a relation between the daidzein and 
genistein levels of food with the ratios of these isoflavones in plasma and urine was 
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evident, however some effects of soy food matrix were observed.  Soy milk intake 
resulted in greater genistein bioavailability than daidzein compared to their relative 
amounts in the soy milk, while resistant starch intake appeared to increase daidzein 
excretion more than genistein.   Furthermore, there was a particular finding of high 
occurrence of equol in plasma in the third study examining the combination of soy with 
oil; this was suggested to be due to the higher proportions of daidzein and glycitein than 
genistein in the soy germ product ingredient of the cereal.   
 
Overall, there appears to be the potential for probiotic and prebiotic foods and the soy 
matrix isoflavone composition to influence soy isoflavone bioavailability.  These 
findings are important in relation to physiological activities of soy foods as the 
isoflavones differ in their bioactivity and require further investigation.  Further, in 
relation to lipid effects of soy consumption, baseline levels of total and LDL cholesterol 
were both significantly inversely correlated with subsequent lipid changes with soy 
intake.  In addition, there were beneficial additive hypocholesterolemic effects of soy 
with probiotic and prebiotic foods and with DHA-rich oil supplementation.  In 
conclusion, the bioavailability of isoflavones from soy is affected by other dietary 
components and the soy matrix in which they are contained.  This did not appear to 
influence lipid effects which were modest and only significant when soy was consumed 
concurrently with other dietary components also known to produce beneficial effects.  
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